Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia (Q44851706)

6 December 2017

title

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia (English)

1 reference

6 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Yiguo Hu

1

0 references

Michael Hallek

7

object named as

Michael Hallek

1 reference

6 December 2017

Yuhua Liu

2

1 reference

6 December 2017

Shawn Pelletier

3

1 reference

6 December 2017

Elisabeth Buchdunger

4

1 reference

6 December 2017

Markus Warmuth

5

1 reference

6 December 2017

Doriano Fabbro

6

1 reference

6 December 2017

Richard A Van Etten

8

1 reference

6 December 2017

Shaoguang Li

9

1 reference

6 December 2017

language of work or name

English

0 references

publication date

18 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

36

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

453-461

1 reference

6 December 2017

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Molecular mechanisms of transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Studying the pathogenesis of BCR-ABL+ leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Autoinhibition of Bcr-Abl through its SH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNG1343

21 January 2018

Identifiers

DOI

10.1038/NG1343

1 reference

6 December 2017

1 reference